Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 8/20 | 0.62 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | BCHE | P06276 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8204776 | 1.00 | CASR (0.62) | CASRMEN1KMT2ABCHESMN1; SMN2 | |
| SCHEMBL4999769 | 0.91 | CASR (0.62) | CASRMEN1KMT2ABCHESMN1; SMN2 | |
| SCHEMBL1032688 | 0.89 | CASR (0.56) | CASRMEN1KMT2ABCHESMN1; SMN2 | |
| SCHEMBL5267733 | 0.89 | MEN1 (0.70) | CASRMEN1KMT2ABCHETDP1 | |
| SCHEMBL5267428 | 0.89 | MEN1 (0.70) | CASRMEN1KMT2ABCHETDP1 | |
| SCHEMBL5270940 | 0.82 | MEN1 (0.62) | CASRMEN1KMT2ABCHETDP1 | |
| SCHEMBL5267222 | 0.81 | MEN1 (0.61) | CASRMEN1KMT2ABCHESMN1; SMN2 | |
| SCHEMBL5272357 | 0.80 | MEN1 (0.60) | CASRMEN1KMT2ABCHETDP1 | |
| SCHEMBL5266218 | 0.80 | MEN1 (0.60) | CASRMEN1KMT2ABCHESMN1; SMN2 | |
| SCHEMBL5267631 | 0.80 | CASR (0.62) | CASRMEN1KMT2ABCHESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2079525-A1 | CALCIUM RECEPTOR MODULATING AGENTS | Amgen Inc. (US) | 2009-07-22 | — | — | EP | claimed |
| US-20080221101-A1 | Calcium receptor modulating agents | AMGEN INC. (US) | 2008-09-11 | — | — | US | claimed |
| WO-2008057282-A1 | CALCIUM RECEPTOR MODULATING AGENTS | AMGEN INC. (US) | 2008-05-15 | — | — | WO | claimed |
| US-8349831-B2 | Osteoporosis, bone disorders, or diseases associated with excessive secretion of PTH, such as hyperparathyroidism; reduce or inhibit parathyroid hormone (PTH) secretion | AMGEN INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-20080221101-A1 | Calcium receptor modulating agents | AMGEN INC. (US) | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221101-A1 | Calcium receptor modulating agents | CASR, RYR1, RYR2 | CASR 1/4885MEN1 2531/4885KMT2A 4786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.